Icon

VIVELLE (nda020323)- (0.025MG/24HR,0.0375MG/24HR,0.05MG/24HR,0.075MG/24HR,0.1MG/24HR)

ESTRADIOL SANDOZ
0.025MG/24HR,0.0375MG/24HR,0.05MG/24HR,0.075MG/24HR,0.1MG/24HR
No No
2011-Apr-05 Expired
None None
None No
Vivelle is indicated in the following: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. 4. Prevention of postmenopausal osteoporosis.
0 0 0
Total Other Developers 5
Drugs with Suitability No
0.025MG/24HR ** ** - - -
0.0375MG/24HR ** ** - - -
0.05MG/24HR ** ** - - -
0.075MG/24HR ** ** - - -
0.1MG/24HR ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.